| |
See how once-daily ONEXTON Gel treats comedonal & inflammatory acne lesions here.1
INDICATION
ONEXTON (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/3.75% is indicated for the topical treatment of acne vulgaris in patients 12 years of age or older.
| IMPORTANT SAFETY INFORMATION |
| • |
|
ONEXTON Gel is contraindicated in patients with a known hypersensitivity to clindamycin, benzoyl peroxide, any component of the formulation, or lincomycin. |
| |
| • |
|
ONEXTON Gel is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. |
| |
| • |
|
Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin. ONEXTON Gel should be discontinued if significant diarrhea occurs. |
| |
| • |
|
Orally and parenterally administered clindamycin has been associated with severe colitis, which may result in death. |
| |
| • |
|
Anaphylaxis, as well as other allergic reactions leading to hospitalizations, has been reported in postmarketing use of products containing clindamycin/benzoyl peroxide. If a patient develops symptoms of an allergic reaction such as swelling and shortness of breath, they should be instructed to discontinue use and contact a physician immediately. |
| |
| • |
|
The most common local adverse reactions experienced by patients in clinical trials were mild and moderate erythema, scaling, itching, burning and stinging. |
| |
| • |
|
ONEXTON Gel should not be used in combination with erythromycin-containing products because of its clindamycin component. |
| |
| • |
|
ONEXTON Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. A decision should be made whether to use ONEXTON Gel while nursing, taking into account the importance of the drug to the mother. |
| |
| • |
|
Patients should be advised to avoid contact with the eyes or mucous membranes. |
| |
| • |
|
Patients should minimize exposure to natural and avoid artificial sunlight (tanning beds or UVA/B treatment) while using ONEXTON Gel. To minimize exposure to sunlight, protective clothing should be worn and a sunscreen with SPF 15 rating or higher should be used. |
| |
| Click here for full Prescribing Information.
|
|
|
| |
|
|
| |
| |
Reference: 1. ONEXTON [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2014.
|
| * |
Offer valid only for commercially insured patients whose insurance covers ONEXTON Gel. Commercially insured patients whose insurance does not cover ONEXTON Gel may pay more. Cash-paying patients are not eligible. Not valid for patients reimbursed in whole or in part by federal healthcare programs, including Medicare, Medicaid, CHAMPUS, the Department of Veterans Affairs, state maternal and child health block grant programs under 42 U.S.C. section 701 et. seq., state social service block grant programs under 42 U.S.C. section 1397 et. seq., or any other similar federal or state healthcare program. Void where prohibited by law, taxed, or restricted. Void outside the United States. See savings card for full eligibility Terms and Conditions.
|
You have the right to opt out of receiving unsolicited advertisements by email. You may contact us with your opt-out request, along with the email to which your request relates, by telephone at
1-877-540-6501, or by submitting your request to valeantorder@corpcomm.com. Opt-out requests will be honored within 10 business days of receipt. Please be sure to indicate the email address to which your request relates and reason for opt-out.
|
®/TMs are trademarks of Valeant Pharmaceuticals International, Inc. or its affiliates. Any other product or brand names are trademarks of their respective owners.
|
|
|
| |
|
© 2015 Valeant Pharmaceuticals North America LLC.
400 Somerset Corporate Blvd., Bridgewater, NJ 08807
|
DM/ONX/15/0107
|
|
|
|
